← Back to All US Stocks

Wellgistics Health, Inc. (WGRX) Fundamental Analysis & AI Grade 2026

WGRX Nasdaq Wholesale-Drugs, Proprietaries & Druggists' Sundries DE CIK: 0002030763
Updated This Month • Analysis: May 21, 2026 • SEC Data: 2026-03-31
Combined AI Grade
D
88% Confidence
N/A
D
88% Conf
Pending
Analysis scheduled

📊 WGRX Key Takeaways

Revenue: $1.6M
Net Margin: -496.5%
Free Cash Flow: $-3.4M
Current Ratio: 0.09x
Debt/Equity: N/A
EPS: $-0.07
AI Grade: D with 88% confidence
Wellgistics Health, Inc. (WGRX) receives a D fundamental grade with 88% confidence from our AI analysis based on SEC 10-K filings. With revenue of $1.6M, net profit margin of -496.5%, Wellgistics Health, Inc. demonstrates mixed fundamentals in the Market sector. Below is our complete WGRX stock analysis for 2026.

Is Wellgistics Health, Inc. (WGRX) a Good Investment?

Claude

Wellgistics Health exhibits severe financial distress with negative stockholders' equity of -$15.1M indicating technical insolvency. The company is experiencing critical liquidity crisis (0.09x current ratio, $51.7K cash) while burning $3.4M quarterly in operations, making near-term solvency highly questionable despite 28.7% revenue growth.

Wellgistics Health, Inc. Key Strengths (WGRX)

Claude
  • + Revenue growth of 28.7% YoY demonstrates market demand for products
  • + Positive gross profit ($170.2K) indicates viable unit economics at product level
  • + Low revenue base ($1.6M) leaves room for improvement if operational losses are arrested

WGRX Stock Risks: Wellgistics Health, Inc. Investment Risks

Claude
  • ! Negative stockholders' equity of -$15.1M signals technical insolvency; liabilities exceed assets by $15.1M
  • ! Critical liquidity failure: current ratio 0.09x, quick ratio 0.03x, only $51.7K cash available
  • ! Operating cash burn of -$3.4M quarterly with accelerating net losses (-1377.1% YoY) unsustainable
  • ! Debt burden of $27.8M cannot be serviced with current cash generation; maturity risk imminent
  • ! Operating margin of -385.7% indicates structural unprofitability requiring existential restructuring

Key Metrics to Watch

Claude
  • * Quarterly cash runway and monthly operating cash burn rate trajectory
  • * Debt refinancing progress or restructuring negotiations with lenders
  • * Revenue-to-operating-expense ratio improvement and path to operating cash flow breakeven
  • * Stockholders' equity recovery and changes in liquidity ratios (current/quick ratio floor)
  • * Any capital infusions, dilutive financing, or covenant violations

Wellgistics Health, Inc. (WGRX) Financial Metrics & Key Ratios

Revenue
$1.6M
Net Income
$-7.7M
EPS (Diluted)
$-0.07
Free Cash Flow
$-3.4M
Total Assets
$30.1M
Cash Position
$51.7K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

WGRX Profit Margin, ROE & Profitability Analysis

Gross Margin 10.9%
Operating Margin -385.7%
Net Margin -496.5%
ROE N/A
ROA -25.7%
FCF Margin -218.9%

WGRX vs Market Sector: How Wellgistics Health, Inc. Compares

How Wellgistics Health, Inc. compares to Market sector averages

Net Margin
WGRX -496.5%
vs
Sector Avg 12.0%
WGRX Sector
ROE
WGRX 0.0%
vs
Sector Avg 15.0%
WGRX Sector
Current Ratio
WGRX 0.1x
vs
Sector Avg 1.8x
WGRX Sector
Debt/Equity
WGRX 0.0x
vs
Sector Avg 0.7x
WGRX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Wellgistics Health, Inc. Stock Overvalued? WGRX Valuation Analysis 2026

Based on fundamental analysis, Wellgistics Health, Inc. has mixed fundamental signals relative to the Market sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
-496.5%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Wellgistics Health, Inc. Balance Sheet: WGRX Debt, Cash & Liquidity

Current Ratio
0.09x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
150.0%
Interest Coverage
N/A
Long-term Debt
$27.8M

WGRX Revenue & Earnings Growth: 5-Year Financial Trend

WGRX 5-year financial data: Year 2024: Revenue $18.1M, Net Income -$2.9M, EPS $-0.06. Year 2025: Revenue $23.3M, Net Income -$6.9M, EPS $-0.15.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Wellgistics Health, Inc.'s revenue has grown significantly by 29% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.15 indicates the company is currently unprofitable.

WGRX Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-218.9%
Free cash flow / Revenue

WGRX Quarterly Earnings & Performance

Quarterly financial performance data for Wellgistics Health, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $1.6M -$7.7M $-0.07
Q3 2025 $3.0M -$83.1K $-0.04
Q2 2025 $44.5K -$83.1K $-0.01
Q1 2025 $10.9M -$83.1K $0.00

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Wellgistics Health, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$3.4M
Cash generated from operations
Dividends
None
No dividend program

WGRX SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Wellgistics Health, Inc. (CIK: 0002030763)

📋 Recent SEC Filings

Date Form Document Action
May 29, 2026 8-K form8-k.htm View →
May 21, 2026 8-K form8-k.htm View →
May 21, 2026 8-K form8-k.htm View →
May 19, 2026 8-K form8-k.htm View →
May 19, 2026 10-Q form10-q.htm View →

Frequently Asked Questions about WGRX

What is the AI rating for WGRX?

Wellgistics Health, Inc. (WGRX) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.

What are WGRX's key strengths?

Claude: Revenue growth of 28.7% YoY demonstrates market demand for products. Positive gross profit ($170.2K) indicates viable unit economics at product level.

What are the risks of investing in WGRX?

Claude: Negative stockholders' equity of -$15.1M signals technical insolvency; liabilities exceed assets by $15.1M. Critical liquidity failure: current ratio 0.09x, quick ratio 0.03x, only $51.7K cash available.

What is WGRX's revenue and growth?

Wellgistics Health, Inc. reported revenue of $1.6M.

Does WGRX pay dividends?

Wellgistics Health, Inc. does not currently pay dividends.

Where can I find WGRX SEC filings?

Official SEC filings for Wellgistics Health, Inc. (CIK: 0002030763) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is WGRX's EPS?

Wellgistics Health, Inc. has a diluted EPS of $-0.07.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is WGRX's fundamental grade?

Based on our AI fundamental analysis in June 2026, Wellgistics Health, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is WGRX stock overvalued or undervalued?

Valuation metrics for WGRX: ROE of N/A (sector avg: 15%), net margin of -496.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is WGRX's AI grade for 2026?

Our dual AI analysis gives Wellgistics Health, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is WGRX's free cash flow?

Wellgistics Health, Inc.'s operating cash flow is $-3.4M, with capital expenditures of N/A. FCF margin is -218.9%.

How does WGRX compare to other Market stocks?

Vs Default sector averages: Net margin -496.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.09 (avg: 1.8).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 21, 2026 | Data as of: 2026-03-31 | Powered by Claude AI